abstract |
The present disclosure relates to the discovery that thymidine kinase 1(TK-1) is a valuable biomarker in a method of determining the Prognostic Index (PI) of risk stratification in patients with aggressive B-cell lymphoma, particularly diffuse large B-cell lymphoma, DLBCL; to the use of TK-1 in such PIs; also relates to a PI, which comprises the marker TK-1. |